Core Viewpoint - The stock of Kefu Medical (301087) has shown a slight decline, with a closing price of 59.5 yuan on January 14, 2026, down by 1.65% [1] Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, an increase of 6.63% year-on-year [2] - The net profit attributable to the parent company was 260 million yuan, up by 3.3% year-on-year [2] - The net profit after deducting non-recurring items was 222 million yuan, reflecting a year-on-year increase of 1.46% [2] - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, a significant increase of 30.72% year-on-year [2] - The single-quarter net profit attributable to the parent company was approximately 92.83 million yuan, up by 38.68% year-on-year [2] - The single-quarter net profit after deducting non-recurring items was 85.80 million yuan, marking a year-on-year increase of 62.68% [2] - The company's debt ratio stands at 27.37%, with investment income of 18.18 million yuan and financial expenses of -3.77 million yuan [2] - The gross profit margin is reported at 53.35% [2] Market Activity - On January 14, 2026, the net outflow of main funds was 23.53 million yuan, accounting for 3.54% of the total transaction amount [1] - Retail investors saw a net inflow of 17.96 million yuan, representing 2.7% of the total transaction amount [1] - Over the past 90 days, 8 institutions have provided ratings for Kefu Medical, with 7 buy ratings and 1 hold rating [2] - The average target price set by institutions in the last 90 days is 545.6 million yuan [2]
股票行情快报：可孚医疗（301087）1月14日主力资金净卖出2353.15万元